Skip to main content
OpenTrials
Completed

NCT Number: NCT04287712

Detection of Lung Cancer by Plasma Lipids

There are no reliable blood-based tests currently available for early-stage lung cancer diagnosis. We try to establish a highly accurate method for detecting early-stage lung cancer by combining machine learning with untargeted and targeted metabolomics .

Completed

Looking for future studies?

Notify Me

Key information

Conditions

Early-Stage Lung Cancer Lung Diseases Lung Neoplasms Neoplasms Neoplasms by Site Respiratory Tract Diseases Respiratory Tract Neoplasms Thoracic Neoplasms

Age range

18 year and older

Sex eligibility

All sexes

Study type

Observational

Primary location

Peking University People's Hospital

Beijing, Beijing Municipality, 100044, China

About this study

All plasma lipids were first detected by untargeted metabolomics methods and 9 feature lipids of early-stage lung cancer were selected by support vector machine algorithm. Then, a targeted metabolomics method was developed to detect the 9 lipids quantitatively based on multiple reaction monitoring mode. Finally, a detection model was established based on the 9 lipids.

Who can participate

Healthy volunteers accepted: Yes

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • pulmonary nodules or opacity
  • plan to receive surgery

Exclusion criteria

  • history of other malignancies
  • received anti-cancer treatment (chemotherapy, radiotherapy, targeted therapy, etc.) before surgery

Treatment and study plan

Plasma lipids

Diagnostic Test

Plasma lipids were detected by an Ultimate 3000 ultra-high-performance liquid chromatography (UHPLC) system coupled with Q-Exactive MS (Thermo Scientific) . Then a detection model was built based on plasma lipids using machine learning algorithm.

Primary outcomes

  1. Plasma Lipids

    Time frame: All samples were detected together after participants recruitment and sample collection. All samples were detected within 18 months from sample collection.

    A detection model based on 9 lipids were developed, including 3 lysophosphatidylcholines, 5 phosphatidylcholines, and a triglyceride. The 9 lipids were detected by targeted metabolomics by mass spectrometry.

Sponsors and collaborators

Lead sponsor

Peking University People's Hospital

Other

Collaborators

  • Beijing Haidian Hospital
  • Jiangsu Cancer Institute & Hospital
  • Peking University Health Science Center

Registry information

Official study title

Detection of Early-stage Lung Cancer Using Machine Learning and Plasma Metabolomics

Acronym: ELAID

Important dates

Study start
2018
Primary completion
2019
Study completion
2020
First posted
Feb 27, 2020
Registry last updated
Jun 4, 2020

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Related clinical trials

Published trials that share one or more normalized conditions with this study.